# VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

> **NCT05780281** · PHASE3 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 367 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** VIR-7831
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** Remdesivir

## Key facts

- **NCT ID:** NCT05780281
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-16
- **Primary completion:** 2021-06-09
- **Final completion:** 2022-10-04
- **Target enrollment:** 367 (ACTUAL)
- **Last updated:** 2023-12-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05780281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05780281, "VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05780281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*